Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | PHF13 | Q86YI8 | 1/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 6/20 | 0.43 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682666 | 0.81 | L3MBTL1 (1.00) | L3MBTL1SIGMAR1MBTD1HTR7HTR6 | |
| SCHEMBL23682995 | 0.81 | SIGMAR1 (0.79) | L3MBTL1SIGMAR1MBTD1HTR7SFRP1 | |
| SCHEMBL926638 | 0.79 | ALDH1A1 (0.56) | SIGMAR1 | |
| SCHEMBL6034608 | 0.75 | SIGMAR1 (0.83) | L3MBTL1SIGMAR1MBTD1HTR7SFRP1 | |
| SCHEMBL23682845 | 0.73 | PHF13 (1.00) | L3MBTL1PHF13L3MBTL3MEN1KMT2A | |
| SCHEMBL924703 | 0.73 | S100A9 (0.47) | MEN1KMT2A | |
| SCHEMBL23718088 | 0.71 | L3MBTL1 (0.80) | L3MBTL1KMT2A | |
| SCHEMBL4700357 | 0.71 | L3MBTL1 (0.92) | L3MBTL1SIGMAR1MBTD1HTR7MEN1 | |
| SCHEMBL2498510 | 0.70 | L3MBTL1 (0.81) | L3MBTL1SIGMAR1MBTD1HTR7 | |
| SCHEMBL6341348 | 0.70 | POLB (0.74) | L3MBTL1HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | L3MBTL1 3195/4885PHF13 2056/4885L3MBTL3 3097/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | L3MBTL1 228/4885PHF13 1613/4885L3MBTL3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.